In multivariate analysis, a forward stepwise algorithm was implemented and variables were selected if Pvalue was less than .05. Factors associated with postremission survival included age at CR (49 or younger vs 50 to 64, HR 0.59, P= .02; 49 or younger vs 65 or older, HR 0.46, P = .001), NCCN risk (intermediate vs poor, HR 0.54, P < .001), induction regimen (FLAG-Ida vs 3+7, HR 0.62, P = .01), and receiving HSCT (yes vs no, HR 0.68, P = .02).
Factors affecting DFS from time of CR also included age, NCCN risk, induction regimen (FLAG-Ida vs 3+7, HR 0.68, P = .028), and receiving HSCT.
Based on these results, choice of induction therapy can impact postremission survival for patients with nonfavorable NCCN risk AML. Faster time to both CR and HSCT in patients who received induction therapy with FLAG-Ida may partially explain these results, conclude the researchers.
Disclosures: An author declared affiliations with the pharmaceutical industry. For a complete list of disclosures, please refer to the original abstract.
Sohl M, Solomon SR, Morris LE, Holland HK, Zhang X, Bashey A. The choice of induction regimen affects post remission survival of acute myelogenous leukemia (AML) patients with intermediate or poor risk disease. Oral presentation at: American Society of Hematology 60th Annual Meeting & Exposition; December 1-4, 2018; San Diego, CA. Abstract 82.